Cause of Familial Testicular Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00034424
First received: April 27, 2002
Last updated: April 12, 2014
Last verified: April 2014
  Purpose

Background:

People with a family history of testicular cancer may be at increased risk for the disease.

Genetic and clinical studies of patients with testicular cancer and their family members may help clarify the cause of the disease and identify clinical features.

Objectives:

To characterize the clinical features of testicular cancer.

To identify genes that may lead to increased risk of the disease.

To examine emotional and behavioral issues of members of families at increased risk of the disease.

Eligibility:

Males and females from a family with at least two cases of testicular cancer in blood relatives.

Males with testicular cancer in both testicles.

Males with testicular cancer who have an identical twin.

Participants must be at least 12 years of age.

Design:

Participants may take part in Part 1 or Parts 1 and 2 of this 2-part study.

Part 1 participants:

  • Provide a blood or cheek cell sample to obtain DNA for gene studies.
  • Provide permission for researchers to obtain their medical records for review.
  • Complete questionnaires about their personal and family medical history, exposure to factors that might influence the risk of testicular cancer, and their feelings about being a member of a family in which several members have testicular cancer.
  • These data are collected from participants in their home communities.

Part 2 participants:

  • All participants provide a medical history, have a complete physical examination, including routine lab tests, and have an ultrasound test of the abdomen to look at the kidneys.
  • Males have an ultrasound test of the testicles and scrotum.
  • Females have an ultrasound test of the pelvis to look at the ovaries, uterus and fallopian tubes.
  • Males 18 years of age and older provide a semen sample.
  • Some participants have computed tomography (CT) scanning of the chest, abdomen and pelvis instead of kidney ultrasound. Children under 18 years of age may have magnetic resonance imaging (MRI) instead of CT.
  • These data are collected from participants during a 2-day visit to the NIH Clinical Center in Bethesda, MD. Travel costs are covered by the protocol.

Condition
Testicular Neoplasms
Germinoma

Study Type: Observational
Official Title: Multidisciplinary Etiologic Study of Familial Testicular Cancer

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Ascertain new familiies with FTGCTs [ Time Frame: ongoing ] [ Designated as safety issue: No ]
  • Characterize the clinical features of familial TGC [ Time Frame: ongoing ] [ Designated as safety issue: No ]
  • Determine the underlying genetic mechanism for susceptibility to TGCT in families [ Time Frame: ongoing ] [ Designated as safety issue: No ]
  • Evaluate psychosocial issues related to FGCT [ Time Frame: ongoing ] [ Designated as safety issue: No ]

Estimated Enrollment: 1750
Study Start Date: April 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Study population:

Patients must be members of families with familial TGCT as defined below.

Definition of familial TGCT:

The criterion establishing familial TGCT is the presence of:

-at least two cases of documented GCT in blood relatives (at least one of which is testicular in origin),

OR

  • a single family member with bilateral testicular cancer,
  • men with a history of TGCT who are one in a set of identical siblings will also be included in the study.

Case definition:

A case will be determined to have TGCT according to the following criteria:

  • Pathologic confirmation of a germ cell derived tumor arising in the testis. Extragonadal germ cell tumors will also be included.
  • Germ cell derived histologies including: seminoma, germinoma, embryonal carcinoma, endodermal sinus (yolk sac) tumor, gonadoblastoma, choriocarcinoma, teratoma, and mixed germ cell tumor.
  • A case will be determined to have TIN on the basis of pathologic confirmation of intratubular malignant germ cells (ITMGCs) as defined by Burke and Mostofi.

Individuals from participating families who are eligible for this study include:

i) all TGCT cases;

ii) All GCT cases (including those of ovarian or extra-gonadal sites);

iii) all first-degree relatives of each TGCT case;

iv) the spouse(s) of every case if the spouse and case had children who are participating in the study;

v) any blood relative not included in (ii - iii) above who genetically links two cases; and

vi) any blood relative with cancer other than TGCT

vii) family members as described in i) - v) above must be age 12 or greater in order to participate

EXCLUSION CRITERIA:

Families will be deemed ineligible for participation in this study if:

There are not at least two proven cases of GCT in the family, one of which is testicular in origin, unless there is a family member with bilateral testicular cancer;

Deceased TGCT cases lacking both archival sources of tissue for DNA extraction AND lacking surviving spouses and children who are willing to paricipate in the study (unavailability of such persons prohibits inferring the genotype of the deceased individual with TGCT).

Critical informative family members are unwilling to participate (i.e., unwilling to provide written informed consent);

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034424

Contacts
Contact: Jennifer T Loud, C.R.N.P. (301) 594-7642 loudj@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    (888) NCI-1937      
Sponsors and Collaborators
Investigators
Principal Investigator: Jennifer T Loud, C.R.N.P. National Cancer Institute (NCI)
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00034424     History of Changes
Obsolete Identifiers: NCT00039598
Other Study ID Numbers: 020178, 02-C-0178
Study First Received: April 27, 2002
Last Updated: April 12, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Cancer
Genetics
Hereditary
Screening
Behavioral
Testicular Cancer

Additional relevant MeSH terms:
Testicular Diseases
Neoplasms
Testicular Neoplasms
Germinoma
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on August 01, 2014